Reaction
Colostomy reporting signals
As of the last recalculation, Colostomy appears in 1,929 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 16.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Niraparib | 34 | 16.8 | 16.8 |
| Panitumumab | 24 | 16.7 | 16.8 |
| Vedolizumab | 102 | 13.4 | 13.4 |
| Upadacitinib | 95 | 13.2 | 13.2 |
| Risankizumab-Rzaa | 95 | 13.1 | 13.1 |
| Infliximab-Dyyb | 30 | 11.2 | 11.2 |
| Infliximab | 162 | 8.6 | 8.7 |
| Trifluridine And Tipiracil | 8 | 8.1 | 8.1 |
| Ustekinumab | 68 | 7.4 | 7.4 |
| Regorafenib | 7 | 6.5 | 6.5 |
| Adalimumab | 358 | 6.5 | 6.5 |
| Teduglutide | 8 | 6.4 | 6.4 |
| Amantadine | 8 | 5.6 | 5.6 |
| Rucaparib | 4 | 4.9 | 4.9 |
| Umeclidinium | 4 | 4.8 | 4.8 |
| Imatinib Mesylate | 12 | 4.7 | 4.7 |
| Levodopa | 5 | 4.5 | 4.5 |
| Glecaprevir And Pibrentasvir | 4 | 3.9 | 3.9 |
| Certolizumab Pegol | 41 | 3.8 | 3.8 |
| Umeclidinium Bromide And Vilanterol Trifenatate | 5 | 3.2 | 3.2 |
| Palivizumab | 4 | 2.8 | 2.8 |
| Patiromer | 3 | 2.3 | 2.3 |